In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cystectomy. | ElectroMotive drug administration EMDA of Mitomycin C as first-line salvage therapy in high risk BCG failure non muscle invasive bladder cancer 3 years follow-up outcomes